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s aIntroduction:Despite universal newborn screening (NBS), children in the U.S. continue to experience
morbidity and mortality from sickle cell disease and related causes. Recognizing that assessments of
public health services and systems can improve public health system performance and ultimately
health outcomes, this study examined variations in NBS program activities for sickle cell disease.
Methods: Amixed methods study included (1) a 2009 survey of NBS programs based on ten essential
public health services (N¼39 states with ten or more sickle cell births over a 3-year period) and (2) key
informant interviews in 2011 with 13 states that had sufﬁcient Phase 1 survey scores, black births, and
variability in state legislation and geography. Key informants were from 13 NBS programs, 22 sickle cell
treatment centers, and ten advocacy organizations. Analyses were conducted in 2009–2014.
Results: Considerable variability exists across states in program activities and roles. More programs
reported activities oriented to care of individuals—ensuring access to services, coordination, and
provider education; fewer reported planning and analysis activities oriented to statewide policy
development and system change. Numbers of activities were not related to the number of affected
births. In-depth interviews identiﬁed opportunities to enhance activities that support statewide
comprehensive systems of care.
Conclusions: NBS programs perform important public health roles that complement and enhance
clinical services. Nationwide efforts are needed to enable NBS programs to strengthen population-
based functions that are essential to ensuring quality of care for the entire population of children and
families affected by sickle cell disease.
(Am J Prev Med 2016;51(1S1):S39–S47) & 2016 American Journal of Preventive Medicine. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionNew York was the ﬁrst state to implement new-born screening (NBS) for sickle cell disease in1975; by 2006, universal NBS for sickle cell
disease was in place in all U.S. states, Puerto Rico, and the
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rticle under the CC BY-NC-ND license (http://creativecoinitiation of penicillin prophylaxis, and establishment
of comprehensive care.2 NBS has contributed to
decreased morbidity and mortality among those affected
by sickle cell disease and increased receipt of specialized
medical care necessary to manage the disease and its
sequelae.3 However, although notable improvements in
survival for children with sickle cell disease have been
realized, these children continue to experience disabil-
ities, higher mortality, and greater difﬁculty accessing
healthcare services relative to children without sickle cell
disease.4
Healthy People 2020 calls for increasing appropriate
bloodspot NBS and follow-up testing.5 Although variability
in NBS and follow-up has been reported6,7 and the need to
consider NBS in light of public health functions recognized,3
there has been no systematic reporting about the extent of
variability in NBS speciﬁc for sickle cell disease across statesier Inc. This is an
mmons.org/licenses/by-nc-nd/4.0/).
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size of the affected population. The gap is notable despite
sickle cell disease being one of the ﬁrst conditions recom-
mended for NBS.1,8 The lack of information is also concern-
ing given that sickle cell disease disproportionately impacts
populations of African, Mediterranean, Middle Eastern, and
Indian descent,8 many of whom are historically underserved
in terms of healthcare services.
The objective of this study was to assess variability in
NBS program structure and activities for sickle cell
disease in the U.S. A two-phase study was conducted to1. characterize organizational structures and functions of
state NBS programs for sickle cell disease, from initial
screening through longer-term follow-up and system-
level roles; and2. identify facilitators and barriers for developing a
comprehensive public health approach to NBS and
follow-up for sickle cell disease.
For Phase 1, the authors hypothesized that states with
a larger number of affected births would have more-
robust NBS activities speciﬁc to sickle cell disease.
Methods
This mixed methods approach involved quantitative data gathered
through surveys of NBS program directors (Phase 1) and qualitative
data obtained from key informant interviews with stakeholders
(Phase 2). This approach incorporated diverse perspectives to
develop a more complete understanding of NBS activities.9
Study Sample
Phase 1: survey of newborn screening programs. Study
eligibility criteria for states were based on the number of conﬁrmed
or presumed newborns with sickle cell disease as reported in the
2001–2006 National Newborn Screening Information System
database and with input from the study’s Advisory Committee.
A total of 38 states and the District of Columbia were eligible to
participate based on the following:1. twenty-eight states and the District of Columbia—ten or more
conﬁrmed cases of sickle cell disease in newborns over all
3-year periods between 2001 and 2006; and2.Four categories of legislation were identiﬁed to establishten states—ten or more conﬁrmed cases (n¼7) or presumed
cases (n¼3) of sickle cell disease over at least one 3-year period
between 2001 and 2006.
All 39 eligible NBS programs participated in Phase 1.
Phase 2: key informant interviews. Eligibility for inclu-
sion in Phase 2 was informed by input from the study’s Advisory
Committee to achieve purposive sampling and, empirically, reach
saturation of relevant themes. Criteria for participation in Phase 2
included participation in the Phase 1 survey (N¼39); total publichealth function domain summary score from Phase 1 survey of
≥11 (range, 0–38 out of possible score of 50 among the 39 states);
and ≥3,000 live black births in 2007. The cutoff of 11 was selected
based on a natural break in the data and the desire to include states
with sufﬁcient scores to examine NBS activities. Of the 24 states that
met Phase 2 eligibility criteria, 13 were selected. They represented
variability in geographic location, state legislation related to sickle cell
disease, and federal funding for sickle cell–related activities. Attempts
were made to minimize overlap with the seven states participating in
the Registry and Surveillance System pilot being conducted by the
National Heart, Lung, and Blood Institute (NHLBI) and the Centers
for Disease Control and Prevention (CDC).
Within the 13 states, key informants included the NBS Program
Director, director(s) of major sickle cell center(s), and the director of
the state or regional Sickle Cell Disease Association afﬁliate(s) or
major advocacy organization(s).
Key informant interviews were conducted with 17 of 17 represen-
tatives from the 13 NBS programs (ten states provided one key
informant, two states provided two key informants, and one state
provided three key informants); 22 of 26 sickle cell treatment center
directors (one to three centers per state); and 10 of 16 advocacy
organization representatives (zero to two organizations per state) for a
total of 49 key informant interviews.Data Sources and Measures
Phase 1: survey of newborn screening programs.
Surveys of state NBS programs were developed based on prior
literature10 and seven of the ten essential public health services11
derived from the core public health functions of assessment, policy
development, and assurance.12 Services included data assessment and
analysis, community partnerships and mobilization, policy planning
and development, quality assurance, service linkages and coordination,
workforce capacity, and program evaluation. The three essential public
health services not relevant to this project were excluded: diagnosis
and investigation (which is implicit to all NBS programs); research
demonstrations (not relevant at state-level NBS); and information and
education (because of focus on population-based systems and activities
rather than the promotion of individual behavior change). The survey
was piloted with NBS program directors in two states not eligible to
participate and revised accordingly. The survey items comprising each
of six composite domains were adapted from the essential public
health services (Table 1).Abstraction of state legislation related to sickle cell
disease and review of federal funding. A systematic
review of state legislation related to sickle cell disease was conducted
to categorize states with regard to policy actions and guide key
informant sampling from among the 39 states that completed the
Phase 1 survey. This review included statutes and regulations and
excluded executive orders. Data sources included websites of the
National Conference of State Legislatures—Sickle Cell Legislation;
U.S. Laws, Codes, Statutes & Cases—Justia (search terms: sickle,
sickle cell, and hemoglobinopathy); and individual state legislature
websites with searches for statutes and regulations with key terms.1. a commission, committee, or board speciﬁc to sickle cell disease;
2. a program speciﬁc to sickle cell disease;www.ajpmonline.org
Table 1. Newborn Screening for Sickle Cell Disease Survey Items by Public Health Domain (n¼39 States)
Survey items by public health domain n (%)
Data collection and analysis
● Collected population-level data in past 2 yearsa 20 (51.3)
● Analyzed population-level data in past 2 yearsa 13 (33.3)
● Conducted focus groups and/or needs assessment 18 (46.2)
Policy development
● Presented information to state political leaders at least annually 4 (10.3)
● Developed fact sheets for community organizations 18 (46.2)
● Participated in local advocacy coalition 15 (38.5)
● Worked with state medical societies or other organizations to advocate 16 (41.0)
● Produced a plan to address health needs of children with sickle cell disease 7 (17.9)
● Undertook a formal process to develop strategies to improve health of children with sickle cell disease 13 (33.3)
● Produced report on progress toward meeting state health goals 17 (43.6)
● Provided expertise on sickle cell disease to state legislative or regulatory bodies for development of policy or programs 13 (33.3)
● Provided expertise on sickle cell disease to other organizations in state 20 (51.3)
Quality assurance
● Developed standards of care for children with sickle cell disease 11 (28.2)
● Participated in quality improvement of facilities/providers of care 12 (30.8)
● Monitored providers of care/servicesb 14 (35.9)
● Evaluated newborn screening services available to families 10 (25.6)
● Worked with other organizations to collect/analyze data on consumer satisfaction, access issues, quality of care, etc. 10 (25.6)
● Used data for quality improvement 18 (46.2)
Coordination
● Met with stakeholders to coordinate activities to meet needs of children with sickle cell diseasec 33 (84.6)
Workforce development
● Disseminated comprehensive, written education plan for any audience (providers, consumers, policy makers, etc.) 10 (25.6)
● Participated in developing strategies to address workforce shortages for care providers 7 (17.9)
● Targeted care providers for education about sickle cell diseased 24 (61.5)
Access to services
● Tracked and followed up on receipt of caree 32 (82.1)
● Met with service providers to enhance speciﬁc activities/services for familiesf 18 (46.2)
Note: Time frame for activities was past 4 years, unless otherwise noted. All activities are speciﬁc to children with sickle cell disease and their families.
aIncludes one or more of the following: demographic characteristics, SES, health status, receipt of medical services, follow-up case management, and
health outcomes.
bIf responded yes to global question regarding monitoring. Follow-up questions assessed monitoring of managed care health plans, private providers
and facilities, public health programs or services, and local hospital services.
cIncludes one or more of the following groups: university medical facility/school, community organizations, local hospitals, primary care associations,
state medical associations, community health centers, school-based health clinics, hematologists, WIC, Head Start, and other.
dIncludes one or more of the following groups: doctors, nurse midwives, nurse practitioners, nurses, schools, and social workers.
eIncludes one or more of the following: referrals of high-risk infants to specialty care, visit with hematologist, well baby visit in ﬁrst month of life,
appropriate penicillin prophylaxis, inﬂuenza and pneumococcal vaccines, transcranial Doppler ultrasound, and parental instruction in spleen palpation.
fIncludes one or more of the following: identiﬁcation of high-risk infants, treatment options, and other.
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identiﬁes sickle cell disease; and4. a program for NBS that speciﬁcally identiﬁes sickle cell disease.
Of the 39 states, 18 states had no legislation, 14 states had one
category of legislation, six states had two categories, and one state
had three categories.
Additionally, states receiving Federal funding from NHLBI, Health
Resources and Services Administration, and CDC initiatives were
identiﬁed. These included NHLBI Comprehensive Sickle Cell Centers,
Health Resources and Services Administration Sickle Cell Treatment
Demonstration Grants, Health Resources and Services Administration
Sickle Cell Disease and NBS Program grants, and CDC/NHLBI
Registry and Surveillance System for Hemoglobinopathies.
Phase 2: key informant interviews. In-depth, structured
telephone interview guides for each stakeholder type were devel-
oped. Interviews explored factors affecting implementation of
public health activities and services for children with sickle cell
disease. Interviews also elaborated on themes derived from the
quantitative survey and explored issues amenable to qualitative
data collection.
Data Collection and Analysis
Phase 1: surveys of newborn screening programs. Two
trained research assistants collected surveys by phone from May
26, 2009, to September 22, 2009, transcribing responses during the
calls. Exploratory analyses of each of the variables were conducted,
and missed skip patterns, outliers, and missing data were assessed.
The state was the unit of analysis. Descriptive tables and
statistics were used to characterize public health activities.
Using survey data, composite measures were developed to
describe public health services in each state related to NBS for
sickle cell disease (Table 1). Summary scores (and the correspond-
ing domain of essential public health services) related to data
functions, policy functions, quality assurance, coordination and
partnerships, workforce development, and access to services. In
addition, a total cross-domain score was calculated (possible range,
0–50) and activities most and least commonly reported were
identiﬁed for each domain (Table 2). Nonparametric tests
(Mann–Whitney, Kruskal–Wallis) were used to examine associa-
tions between numbers of sickle cell births by state in 2006 and
public health functions and capacities expressed as public health
services.
Phase 2: key informant interviews. Data were collected
from March 17, 2011, to June 15, 2011, in phone interviews
conducted by two trained research assistants and a study inves-
tigator. Extensive notes were taken during the calls. Content
analysis was conducted using an adapted version of Framework
Analysis13 to facilitate the systematic analysis of data through key
stages. First, familiarization or the review of the data took place.
Second, a thematic framework, or an initial coding framework for
each respondent type and for each domain, was identiﬁed; they
were reﬁned during subsequent stages. These frameworks were
developed from a priori issues (e.g., learned from Phase 1 analysis
and discussions with the study’s Advisory Committee) and from
issues emerging during familiarization. Third, charting was used tocreate summaries of data based on headings emerging from the
thematic framework. Charts that were thematic across all respond-
ents rather than sorted by each respondent across all themes were
constructed. All interview data were double coded and consensus
reached between the two reviewers for any discrepancies. Fourth,
patterns, associations, concepts, and explanations in the data were
identiﬁed, in order to create typologies and develop strategies/
recommendations.
Several aspects of program implementation were examined,
consistent with the Donabedian14 framework for evaluation using
the key concepts of structure and process; outcomes were not
assessed in these analyses. Also, contextual factors were explored
with respect to the historic and political environment within which
the sickle cell disease system of care evolved and currently
operates. Study variables within the structure, process, and
context domains derived from the theoretic literature on imple-
mentation, as well as from published studies of local and
state systems interventions.15–21 Themes from states scoring
high in relevant domains from the Phase 1 survey and related
challenges or issues were reported. Analyses were conducted in
2009–2014.
The Johns Hopkins Bloomberg School of Public Health IRB
determined this study to not be human subjects research.Results
Among the 39 respondents who completed Phase 1
surveys (100% participation), 59.0% were NBS directors,
35.9% were NBS coordinators, and 5.1% held other job
titles. On average, they had worked 13.0 years in the
health department (range, 0.5–30 years) and 6.8 years in
their current roles (range, 0.25–30 years). Most respond-
ents (n=23, 59.0%) indicated their programs had staff
designated for hemoglobinopathies. Participants
reported that long-term follow-up for sickle cell disease
is performed by state agency staff (n=3, 7.7%); by
external entities (n=12, 30.8%); and a mix of state agency
staff and external entities (n=12, 30.8%) or not per-
formed (n=12, 30.8%).
More states collected than analyzed population-level
data on child and family characteristics, such as SES,
health status, receipt of medical services, or health
outcomes (n=20, 51.3% vs n=13, 33.3%, respectively,
Table 1). Only ten states (25.6%) collected data on three
or more of these characteristics. Nineteen states reported
no population-level data collection. Eighteen states
(46.2%) conducted focus groups or compiled data for a
needs assessment to learn about children with sickle cell
disease.
Fewer than half of NBS programs engaged in most
policy development activities. Activities related to serving
as a resource for other entities were reported more
frequently than formal policy development and planning
processes. Although 20 (51.3%) provided expertise on
sickle cell disease to other organizations in the state,www.ajpmonline.org
Table 2. Public Health Domain Scores for Newborn Screening for Sickle Cell Disease Survey (n¼39 States)
Public
health
domain
Potential
range
Actual
range M Median SD
Most commonly
reported activities
Least commonly
reported activities
Data
collection
and analysis
0–3 0–3 1.3 1 1.1 • Collected population-
level data on
demographic
characteristics (n¼16)
• Conducted needs
assessment (n¼13)
• Analyzed population-level
data on health status at
birth or socioeconomic
characteristics (both n¼4)
Policy
development
0–9 0–8 3.1 3 2.3 • Provided expertise on
sickle cell disease to
other organizations in
the state (n¼20)
• Developed/
disseminated fact
sheets for community
organizations (n¼18)
• Presented information to
state political leaders at
least annually (n¼4)
• Produced a state plan to
address needs (n¼7)
Quality
assurance
0–9 0–8 2.2 2 2.0 • Used data to improve
quality of services for
families (n¼18)
• Monitored private
providers or facilities
(n¼13)
• Monitored managed care
organizations (n¼2) or local
hospitals (n¼5)
Coordination 0–11 0–8 2.9 2 2.5 • Coordinated with
university-based
medical facilities/
medical schools (n¼28)
or community
organizations (n¼20)
• Coordinated with WIC or
Head Start (both n¼3)
Workforce
development
0–8 0–7 2.1 1 2.1 • Targeted education to
physicians (n¼21) or
nurses (n¼16)
• Developed education plan
for policy makers or birthing
facility staff (both n¼3)
Access to
services
0–10 0–9 3.9 4 2.4 • Tracked if children
received penicillin
prophylaxis (n¼27) or
kept a visit with
hematologist (n¼26)
• Tracked if children received
transcranial Doppler
ultrasound (n¼5) or
parents received education
about spleen palpation
(n¼6)
Total 0–50 0–38 15.6 14 9.4
WIC, Special Supplemental Nutrition Program for Women, Infants and Children.
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state political leaders and seven (17.9%) produced a plan
to address the health needs of children with sickle cell
disease.
Eleven (28.2%) programs participated in developing
standards of care for children with sickle cell disease.
Twelve (30.8%) participated in quality improvement
activities of facilities or providers of care. Only ten
(25.6%) reported that they evaluated the NBS services
available to families. However, 18 (46.2%) programs
reported using data for quality improvement.
Workforce development activities included providing
education about sickle cell disease for healthcare profes-
sionals (n¼24, 61.5%) and, less frequently, disseminatingJuly 2016comprehensive written education plans (n¼10, 25.6%)
or developing strategies to address workforce shortages
(n¼7, 17.9%).
Most respondents reported that they met with stake-
holders to coordinate services for children with sickle cell
disease and track receipt of care (n¼33, 84.6% and n¼32,
82.1%, respectively). Twenty-seven states (69.2%)
reported having processes to track receipt of penicillin
prophylaxis, two thirds of which do so until at least age
18 years. Twenty-six states (67%) tracked if hematology
visits were kept, and 11 states (28.2%) tracked receipt of
inﬂuenza and pneumococcal vaccines.
Numbers of activities were not related to the numbers
of affected births (all p40.05).
Table 3. Themes From Key Informant Interviews With Newborn Screening Stakeholders, by Public Health Domain (n¼13
States)
Public
health
domain Selected activities among high scoring states Related challenges or issues
Data
collection
and analysis
• Disseminated questionnaires to individual providers
or contracted treatment centers on quarterly or
annual basis to ensure children were in care
• Used secondary data (e.g., hospital data, Medicaid
claims) for comprehensive needs assessments and
activity planning
• Limited capacity to analyze data from providers or
secondary sources
• Most data collection/analysis activities are not truly
population level given population mobility, loss to
follow-up
Policy
development
• Convened newborn screening advisory committees/
hemoglobinopathies working groups
• Created state plans/consortia with key stakeholders
• Used a regular planning cycle that coincided with
grant funding for treatment centers to assess needs
and inform programs
• Collaborated with state Medicaid or children with
special health care needs programs
• Held annual family day at state capitol to increase
awareness of sickle cell disease among policy makers
• Demographic changes in states with increasing
Hispanic and African populations
• Lack of funding for planning or fully implementing
plans and programs
• Reliance on dedicated individuals (advocates,
specialists) who drive policy and programming and are
difﬁcult to replace
Quality
assurance
• Developed standards of care (e.g., care pathways for
emergency department visits, pain management,
medical home) in consultation with stakeholders at
the state or regional level
• Leveraged contracts (funded or unfunded) with
designated treatment centers to set standards, and to
monitor and evaluate activities
• Conducted annual newborn screening program
evaluations that included parent satisfaction surveys
• Utilized newborn screening program–funded
hemoglobin follow-up coordinator at treatment
centers to track and reduce time to specialist referral
• Reported to state legislature on meeting goals for
penicillin prophylaxis
• Reliance on treatment centers/specialists to develop
standards of care; perception of limited role for
newborn screening program
• Most quality improvement activities conducted at
individual treatment centers; not statewide and not
coordinated with or led by newborn screening
program
Coordination • Held annual conferences that included professional
organizations, churches, community-based
organizations, etc.
• Convened contracted treatment centers annually to
increase coordination and communication
• Created memoranda of understanding or other
agreements with community-based organizations so
information on positive screens/trait could be sent to
them and they could do outreach
• Automatically referred affected children to children
with special health care needs case management,
early intervention; collaborated with school nurses
• Difﬁculty engaging primary care physicians across the
state; many individuals each with very few affected
patients
• Collaborations with community-based organizations
vary greatly depending on their size, number, history
of leadership, and involvement with newborn
screening program and other organizations
• Lack of mechanisms to encourage coordination and
communication across treatment centers
Workforce
development
• Provided updated information on sickle cell disease
for clinicians and families in print and online
• Held annual symposia or meetings to provide
education to a range of providers and consumers
• Created a written education plan for clinicians;
comprehensive treatment handbook
• Funded local newborn screening projects to provide
outreach and education to providers (example: survey
of school nurses to inform education efforts)
• Trained counselors at community-based organizations
to provide trait counseling to families
• Need for increased knowledge among care providers
in emergency departments, urgent care centers in
treating sickle cell crises
• Lack of providers for adolescents transitioning out of
pediatric specialty care
(continued on next page)
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Table 3. Themes From Key Informant Interviews With Newborn Screening Stakeholders, by Public Health Domain (n¼13
States) (continued)
Public
health
domain Selected activities among high scoring states Related challenges or issues
Access to
services
• Increased access to care through mobile clinics in
rural areas or collaborations with community health
centers
• Used regional social workers or newborn screening
program–funded coordinators at treatment centers to
ensure follow-up
• Developed computer systems that allow newborn
screening program and treatment centers to share
information about screening results, treatment plans,
etc.
• Conducted focus groups with parents to evaluate
access to care
• Tracked receipt of services (when number of
treatment centers is small)
• Most states track children only until conﬁrmatory
diagnosis or initiation of specialty care
• Size/structure of state and location/number of
treatment centers may have a signiﬁcant impact on
follow-up and tracking activities
• Few states reported transition services for
adolescents moving on to adult care
Minkovitz et al / Am J Prev Med 2016;51(1S1):S39–S47 S45The mean total cross-domain score was 15.6
(SD¼9.4) out of a possible score of 50 and actual range
of 0–38 (Table 2). For each public health domain, mean
and median scores were less than the midpoint of the
range. Common themes from the key informant inter-
views were identiﬁed for each domain (Table 3). The
activities reported by higher-scoring states reﬂected
strategic use of public agency tools (e.g., contracts,
memoranda of understanding, planning and reporting
cycles) as levers to build system capacity and promote a
comprehensive approach to quality care. These higher-
scoring programs also often served as conveners, creat-
ing focal points for planning, policy development, and
capacity-building activities. Challenges comprised a mix
of issues, including those mutable in the short term with
additional resources (e.g., limited capacity for data analysis
or implementing programs); those amenable to quality
improvement activities (e.g., need to engage primary care
physicians, need for coordination mechanisms across
treatment centers); and those that may be more intractable
or require substantial resource commitments (e.g., reliance
on individual leaders to shoulder efforts, variability in
capacity of community organizations).
Discussion
Using a public health services and systems approach,
considerable variability was observed across states in pro-
gram roles and activities related to NBS and follow-up for
sickle cell disease. More programs report activities oriented to
care of individuals—ensuring access to services, coordination,
and education for providers; fewer report policy development
and data analysis activities oriented to statewide policy
and systems change. Variability in program activities is notJuly 2016related to number of sickle cell disease–affected births. This
may be due to limited funding, lack of political will, low
priority on the public health agenda, ineffective advocacy, or
challenges of collaborating or changing policies/practices in
some states with more affected births.
The ﬁndings suggest a need for enhanced efforts to
strengthen population-based functions that support
statewide comprehensive systems of care for children
affected by sickle cell disease. These efforts are made even
more necessary by demographic shifts in many states,
growing accountability by the healthcare sector for
population-level outcomes, and a heightened recognition
of health disparities. Moreover, recent advances in health
information technology22,23 and administrative data
linkages24 may provide opportunities to generate pop-
ulation-level data and encourage pooled resources to
enhance analytic capacity. The performance evaluation
and assessment scheme,25 in combination with quality
indicators speciﬁc to sickle cell disease (including meas-
ures for genetic counseling and penicillin prophylaxis),26
provide opportunities for states to use quality improve-
ment processes to promote population health.
To date, federal investments in demonstration pro-
grams and private sector advocacy efforts27 have not
enabled NBS programs to reach their full potential or
maintain gains already achieved. In the current economic
environment, substantially more resources are unlikely to
be available to bolster systems of care for children
affected by sickle cell disease. However, promising
practices do exist in many states. Working together,
federal public health leaders and national professional
and consumer/advocacy organizations could draw on
those practices to formulate model program elements
and provide and guide progress nationwide.
Minkovitz et al / Am J Prev Med 2016;51(1S1):S39–S47S46Limitations
Several limitations are noted. First, data were collected
from 2009 to 2011, and NBS programs have evolved with
expansion of the Recommended Uniform Screening
Panel, recommendations for implementing health infor-
mation technology, and implementation of quality
improvement initiatives in selected states.28 However,
despite demonstration projects, fundamental gaps persist
regarding public health functions. Second, these assess-
ments depend on respondent knowledge and experience;
to facilitate accuracy, surveys were shared in advance and
additional participants joined calls as appropriate. Third,
social desirability bias may have led some to overestimate
achievements; however, varied responses with regard to
public health services and triangulated qualitative
responses within and across states suggests a willingness
to report accurately. Fourth, there were small sample
sizes with states as the unit of analysis; however, no other
states had sufﬁcient number of births to be included.
Also, for key informant interviews, saturation was
reached for most themes, suggesting adequate numbers
of study participants. Finally, the impact of alternative
organization and delivery strategies on health outcomes
that would strengthen public health services and systems
approach was not examined.29 However, strategies were
noted that study participants across stakeholder groups
identiﬁed in states with favorable public health services
and systems domain scores.
This examination of variability in NBS programs also
beneﬁted from several strengths. The mixed methods
design enabled the authors to validate and elaborate on
survey responses. Relevant themes were identiﬁed for
state agencies seeking to assess their functioning relative
to other states and federal agencies charged with sup-
porting the development of state public health capacity.
The ﬁndings also reﬂect contextual factors regarding
states’ organization of services and development of
collaborative relationships. In addition, stakeholders
outside the public health sector were included to encom-
pass community organizations as well as public health
agencies and healthcare providers, recognizing each of
their contributions to population health.30
Conclusions
Current NBS programs are situated to perform impor-
tant public health roles that complement and enhance
clinical services, fulﬁlling statewide planning, quality
assurance, and policy functions that are beyond the
purview of individual clinical centers but are essential
to ensuring quality of care for the entire population of
affected children and families. The ﬁndings of variability
across NBS programs with regard to public healthfunctions for sickle cell disease suggest the need to
pursue strategies that enable public health NBS programs
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